These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 30191159)

  • 1. Targeting Root Cause by Systemic scAAV9-h
    Fu H; Zaraspe K; Murakami N; Meadows AS; Pineda RJ; McCarty DM; Muenzer J
    Mol Ther Methods Clin Dev; 2018 Sep; 10():327-340. PubMed ID: 30191159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the Root Cause of Mucopolysaccharidosis IIIA with a New scAAV9 Gene Replacement Vector.
    Bobo TA; Samowitz PN; Robinson MI; Fu H
    Mol Ther Methods Clin Dev; 2020 Dec; 19():474-485. PubMed ID: 33313335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional correction of neurological and somatic disorders at later stages of disease in MPS IIIA mice by systemic scAAV9-hSGSH gene delivery.
    Fu H; Cataldi MP; Ware TA; Zaraspe K; Meadows AS; Murrey DA; McCarty DM
    Mol Ther Methods Clin Dev; 2016; 3():16036. PubMed ID: 27331076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-invasive intravenous administration of AAV9 transducing iduronate sulfatase leads to global metabolic correction and prevention of neurologic deficits in a mouse model of Hunter syndrome.
    Laoharawee K; Podetz-Pedersen KM; Nguyen TT; Singh SM; Smith MC; Belur LR; Low WC; Kozarsky KF; McIvor RS
    Mol Genet Metab Rep; 2023 Mar; 34():100956. PubMed ID: 36704405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Broad functional correction of molecular impairments by systemic delivery of scAAVrh74-hSGSH gene delivery in MPS IIIA mice.
    Duncan FJ; Naughton BJ; Zaraspe K; Murrey DA; Meadows AS; Clark KR; Newsom DE; White P; Fu H; McCarty DM
    Mol Ther; 2015 Apr; 23(4):638-47. PubMed ID: 25592334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of Neurocognitive Deficiency in Mucopolysaccharidosis Type II Mice by Central Nervous System-Directed, AAV9-Mediated Iduronate Sulfatase Gene Transfer.
    Laoharawee K; Podetz-Pedersen KM; Nguyen TT; Evenstar LB; Kitto KF; Nan Z; Fairbanks CA; Low WC; Kozarsky KF; McIvor RS
    Hum Gene Ther; 2017 Aug; 28(8):626-638. PubMed ID: 28478695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Near-Complete Correction of Profound Metabolomic Impairments Corresponding to Functional Benefit in MPS IIIB Mice after IV rAAV9-hNAGLU Gene Delivery.
    Fu H; Meadows AS; Ware T; Mohney RP; McCarty DM
    Mol Ther; 2017 Mar; 25(3):792-802. PubMed ID: 28143737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of a novel mucopolysaccharidosis type II mouse model and recombinant AAV2/8 vector-mediated gene therapy.
    Jung SC; Park ES; Choi EN; Kim CH; Kim SJ; Jin DK
    Mol Cells; 2010 Jul; 30(1):13-8. PubMed ID: 20652491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A GLP-Compliant Toxicology and Biodistribution Study: Systemic Delivery of an rAAV9 Vector for the Treatment of Mucopolysaccharidosis IIIB.
    Meadows AS; Duncan FJ; Camboni M; Waligura K; Montgomery C; Zaraspe K; Naughton BJ; Bremer WG; Shilling C; Walker CM; Bolon B; Flanigan KM; McBride KL; McCarty DM; Fu H
    Hum Gene Ther Clin Dev; 2015 Dec; 26(4):228-42. PubMed ID: 26684447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Blood-Brain-Barrier-Penetrating Anti-human Transferrin Receptor Antibody Fusion Protein for Neuronopathic Mucopolysaccharidosis II.
    Sonoda H; Morimoto H; Yoden E; Koshimura Y; Kinoshita M; Golovina G; Takagi H; Yamamoto R; Minami K; Mizoguchi A; Tachibana K; Hirato T; Takahashi K
    Mol Ther; 2018 May; 26(5):1366-1374. PubMed ID: 29606503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of cerebrospinal fluid heparan sulfate as a biomarker of neuropathology in a murine model of mucopolysaccharidosis type II using high-sensitivity LC/MS/MS.
    Tanaka N; Kida S; Kinoshita M; Morimoto H; Shibasaki T; Tachibana K; Yamamoto R
    Mol Genet Metab; 2018 Sep; 125(1-2):53-58. PubMed ID: 30064964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delivery of an Adeno-Associated Virus Vector into Cerebrospinal Fluid Attenuates Central Nervous System Disease in Mucopolysaccharidosis Type II Mice.
    Hinderer C; Katz N; Louboutin JP; Bell P; Yu H; Nayal M; Kozarsky K; O'Brien WT; Goode T; Wilson JM
    Hum Gene Ther; 2016 Nov; 27(11):906-915. PubMed ID: 27510804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzyme replacement therapy (ERT) procedure for mucopolysaccharidosis type II (MPS II) by intraventricular administration (IVA) in murine MPS II.
    Higuchi T; Shimizu H; Fukuda T; Kawagoe S; Matsumoto J; Shimada Y; Kobayashi H; Ida H; Ohashi T; Morimoto H; Hirato T; Nishino K; Eto Y
    Mol Genet Metab; 2012 Sep; 107(1-2):122-8. PubMed ID: 22704483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of systemic high dose enzyme replacement therapy on the improvement of CNS defects in a mouse model of mucopolysaccharidosis type II.
    Cho SY; Lee J; Ko AR; Kwak MJ; Kim S; Sohn YB; Park SW; Jin DK
    Orphanet J Rare Dis; 2015 Oct; 10():141. PubMed ID: 26520066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of GAG storage in MPS II mouse model following implantation of encapsulated recombinant myoblasts.
    Friso A; Tomanin R; Alba S; Gasparotto N; Puicher EP; Fusco M; Hortelano G; Muenzer J; Marin O; Zacchello F; Scarpa M
    J Gene Med; 2005 Nov; 7(11):1482-91. PubMed ID: 15966019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. "Supercharged Cells" for delivery of recombinant human iduronate-2-sulfatase.
    Pan D; Jonsson JJ; Braun SE; McIvor RS; Whitley CB
    Mol Genet Metab; 2000 Jul; 70(3):170-8. PubMed ID: 10924271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Restoration of central nervous system alpha-N-acetylglucosaminidase activity and therapeutic benefits in mucopolysaccharidosis IIIB mice by a single intracisternal recombinant adeno-associated viral type 2 vector delivery.
    Fu H; DiRosario J; Kang L; Muenzer J; McCarty DM
    J Gene Med; 2010 Jul; 12(7):624-33. PubMed ID: 20603889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II.
    Garcia AR; DaCosta JM; Pan J; Muenzer J; Lamsa JC
    Mol Genet Metab; 2007 Jun; 91(2):183-90. PubMed ID: 17459751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hematopoietic Stem Cell Gene Therapy Corrects Neuropathic Phenotype in Murine Model of Mucopolysaccharidosis Type II.
    Wakabayashi T; Shimada Y; Akiyama K; Higuchi T; Fukuda T; Kobayashi H; Eto Y; Ida H; Ohashi T
    Hum Gene Ther; 2015 Jun; 26(6):357-66. PubMed ID: 25761450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement in behaviour after substrate deprivation therapy with rhodamine B in a mouse model of MPS IIIA.
    Roberts AL; Rees MH; Klebe S; Fletcher JM; Byers S
    Mol Genet Metab; 2007; 92(1-2):115-21. PubMed ID: 17681480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.